HUANG Li-rong;LV Teng-rong;PAN Gui-qiu;CAO Shou-chun;ZHANG Wei;HOU Yu-ting;LI Ming-li;LI Yan-ping;Center for Prevention and Control of Diseases;Objective To evaluate the safety and immunogenicity of freeze-dried rabies vaccine(Vero cells) for human use in healthy population at ages of 10 ~ 60 years.Methods A randomized(1 ∶ 1),blind,positive-controlled trial involving 1 200 healthy subjects at 10 ~ 60 years of age was conducted in Cenxi City and Cangwu County of Guangxi Zhuang Autonomous Region.The subjects were immunized with freeze-dried rabies vaccine(Vero cells)for human use on days 0,3,7,14 and 28,using a commercial product of the same kind as control.Local and systemic adverse reactions were observed within 42 d,while serum samples were collected 14 and 42 d after the first immunization and determined for neutralizing antibody against rabies virus by rapid fluorescence focus inhibition test(RFFIT),based on which the GMC of antibody was calculated.Results A total of 1 199 subjects were observed for safety,of whom the systemic adverse reaction rates in trial(600 cases)and control(599 cases)groups were 12.33% and 18.03% respectively,which showed significant difference(P < 0.05).The common symptom of systemic reactions was fever,of which the incidence rates in trial and control groups were 8.00% and 13.19% respectively.However,the local adverse reaction rates in trial and control groups were 5.33% and 10.52% respectively,which showed significant difference(P < 0.05).The symptoms of local adverse reactions were mainly pain,of which the incidence rates were 4.17% and 8.85% respectively.A total of1 147 subjects were observed for immunogenicity,of whom the antibody positive conversion rates in trial(571 cases)and control(576 cases) groups were 100.00% and 99.83% respectively on day 14 and both 100.00% on day 42 after the first immunization,which showed no significant difference(P > 0.05).The GMCs of antibodies were 8.94 and 7.96 IU / ml on day 14,and 7.26 and 15.04 IU / ml on day 42 after the first immunization,respectively,which showed significant difference(P < 0.05).Conclusion The freeze-dried rabies vaccine(Vero cells)for human use showed high safety and immunogenicity.
2017 03 v.30 [Abstract][OnlineView][Download 213K]